Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for argenx SE's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARGX vs VRTX, REGN, RVMD: Total Payout Ratio Comparison
For the Biotechnology subindustry, argenx SE's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Total Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where argenx SE's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a Total Payout Ratio of 0.00 as of Aug. 19, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on argenx SE and its competitors.
Is argenx SE's Total Payout Ratio too high?
argenx SE's current Total Payout Ratio is 0.00. Overall, argenx SE has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Total Payout Ratio compare to VRTX and REGN?
argenx SE's Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on argenx SE and its competitors. argenx SE's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Modestly Undervalued. The stock's GF Value™ is $1,445.30, compared to a current price of $1,032.86 — trading 28.5% below its estimated fair value. The current Total Payout Ratio is 0.00. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For argenx SE (ARGX), the current Total Payout Ratio is 0.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $1,032.86 is trading 28.5% below its estimated GF Value™ of $1,445.30.
GuruFocus considers argenx SE to be Modestly Undervalued.
Key valuation signals for ARGX:
Total Payout Ratio: 0.00
GF Value™: $1,445.30 vs. price of $1,032.86 (28.5% below fair value)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for ARGX
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
